The complete oral GLP-1 guide

For as long as semaglutide, tirzepatide, and liraglutide have existed, GLP-1 medications have meant needles. Weekly injections. Titration schedules measured in clicks of a pen. That changed in December 2025 when the FDA approved a 25 mg oral Wegovy tablet for weight management, and again in April 2026 when Eli Lilly's Foundayo became the second FDA-approved oral GLP-1 designed specifically for weight loss.

At the same time, an entirely separate industry — compounded oral GLP-1s sold through telehealth platforms as sublingual drops, dissolvable tablets, lozenges, and gummies — has expanded rapidly. Some of it is legitimate. Some of it is marketing dressed as medicine. This guide walks you through both worlds, plainly and in detail.

What "oral GLP-1" means in 2026

A GLP-1 receptor agonist is a drug that mimics glucagon-like peptide-1, a hormone your gut naturally releases after meals. It slows gastric emptying, signals fullness to the brain, and helps regulate blood sugar. The net effect for most people who take one: less hunger, smaller portions, and meaningful weight loss over time.

The problem has always been that peptides don't survive the stomach. Stomach acid breaks them apart, and even what's left has a hard time crossing the intestinal wall intact. For decades, injection was the only way to reliably get a GLP-1 into your bloodstream. In 2019, Novo Nordisk cracked part of that problem with a technology called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that briefly raises stomach pH and helps peptides absorb through the stomach lining. That's what made Rybelsus possible — the first oral GLP-1 pill, approved for type 2 diabetes.

Six years later, SNAC technology finally scaled up to an obesity-indicated dose: the 25 mg Wegovy pill. And Eli Lilly took a different approach entirely: they developed orforglipron (marketed as Foundayo), a small-molecule GLP-1 agonist that doesn't need permeation enhancers because it's not a peptide. It absorbs naturally through the gut like any conventional oral drug.

So in 2026, "oral GLP-1" can mean any of several distinct things — and the differences matter.

The four oral formats explained

Despite what some telehealth platforms imply, these formats are not interchangeable. Each has different absorption mechanics, different evidence bases, and different regulatory status.

1. Daily swallowed tablets (FDA-approved)

The Wegovy pill, Foundayo, and Rybelsus are all swallowed tablets taken once daily. These are the only oral GLP-1 formats with published phase 3 efficacy data in humans and FDA approval. They went through the full regulatory review process: safety, efficacy, manufacturing quality, and labeling are all reviewed before they can be sold.

2. Orally dissolving tablets (ODTs)

Compounded tablets designed to dissolve in the mouth over 30–60 seconds, often flavored. Companies like MangoRx and Sprout Health use this format for compounded semaglutide. The pharmacology is straightforward — the drug is still semaglutide — but ODTs bypass the stomach-acid problem by dissolving in saliva and (theoretically) absorbing through the oral mucosa. Important caveat: there are no published human efficacy trials for ODT semaglutide. Absorption estimates are extrapolated from preclinical animal data and from what's known about other sublingual peptide drugs.

3. Sublingual drops and liquid formulations

Compounded semaglutide (or "oral tirzepatide") suspended in a liquid, administered with a dropper. The user holds the liquid under the tongue for 60–90 seconds, then swallows any remainder. SHED and several other telehealth platforms sell this format. Same caveat: preclinical absorption data only; no human efficacy studies. The mechanism is plausible (sublingual absorption of small amounts of drug), but the actual clinical outcomes aren't documented the way they are for FDA-approved drugs.

4. Lozenges and troches

Compounded medications in a flavored, slowly-dissolving solid form. Similar theoretical absorption pathway to ODTs but with a slower release. Less common in the telehealth market than drops or ODTs. Same regulatory status: compounded, not FDA-approved.

FDA-approved oral GLP-1 drugs

Three drugs currently hold FDA approval for oral administration. Two are indicated for weight management; one for type 2 diabetes (with off-label weight-loss use).

Wegovy pill (oral semaglutide 25 mg)

Approved December 22, 2025. Launched through NovoCare Direct pricing in January 2026. Manufactured by Novo Nordisk. A daily tablet taken on an empty stomach with no more than 4 ounces of plain water, followed by a 30-minute wait before any food, drink, or other medication.

The pivotal trial was OASIS 4, published in the New England Journal of Medicine. In adults with obesity or overweight (without type 2 diabetes), oral semaglutide 25 mg produced a mean body-weight reduction of approximately 13.6% at 64 weeks under the treatment-policy estimand, and approximately 16.6% among adherent participants. Those numbers put the pill firmly in the range of injectable semaglutide (the weekly 2.4 mg dose studied in STEP 1 produced about 14.9% mean reduction) — a meaningful result for an oral drug.

Pricing: $149/month self-pay for starter doses (1.5 mg) through NovoCare Direct. Maintenance doses (9 mg, 25 mg) are priced higher — around $299/month self-pay. Commercial insurance coverage, when it exists, can reduce patient cost to roughly $25/month.

Foundayo (orforglipron)

Approved April 1, 2026. Launched through LillyDirect on April 6, 2026. Manufactured by Eli Lilly. A daily tablet with no food or water restrictions — a major adherence advantage over the Wegovy pill.

Orforglipron is structurally different from semaglutide. It's a non-peptide small molecule designed for oral absorption from the ground up. No SNAC permeation enhancer needed; no strict fasting window required before dosing. The pivotal trial was ATTAIN-1, published in the New England Journal of Medicine in 2025. At the 36 mg maintenance dose, participants lost approximately 11.2% of body weight over 72 weeks — meaningful but somewhat less than injectable semaglutide or tirzepatide.

Pricing: $149/month self-pay for the starter dose (0.8 mg) through LillyDirect. Maintenance pricing is still being finalized as the drug rolls out through pharmacies.

Rybelsus (oral semaglutide 14 mg)

Approved in 2019 for type 2 diabetes. Manufactured by Novo Nordisk. Same food/water rules as the Wegovy pill. Dose caps at 14 mg daily — roughly half the obesity-indicated Wegovy pill dose.

Weight loss from Rybelsus has been studied mostly as a secondary outcome in diabetes trials. In the PIONEER program, Rybelsus produced modest weight reductions (around 4–5% of body weight at 14 mg). The higher-dose PIONEER PLUS trial — which tested 25 mg and 50 mg of oral semaglutide — showed substantially greater weight loss and was part of the evidence base for approving the 25 mg Wegovy pill.

For people with type 2 diabetes seeking weight loss, Rybelsus is often insurance-covered (which the Wegovy pill usually isn't). For people without diabetes, cash price runs $900–$1,400 per month at retail — functionally unaffordable as an obesity drug unless insurance covers it.

Compounded oral GLP-1s

Compounded medications are prepared by licensed pharmacies from bulk active pharmaceutical ingredients. Under federal law — specifically Section 503A of the Food, Drug, and Cosmetic Act — pharmacies can compound patient-specific medications when there's a demonstrated clinical need (such as a different dosage form, allergen-free alternative, or prior drug shortage).

During the semaglutide and tirzepatide shortages of 2022–2024, compounding pharmacies scaled up enormously to fill telehealth prescriptions. When FDA declared the shortages resolved in 2024–2025, the legal landscape tightened significantly. Telehealth compounding is now under much more regulatory scrutiny than it was two years ago.

What the evidence actually shows for compounded oral GLP-1s

Here's the honest picture: for most compounded oral semaglutide formulations (drops, ODTs, lozenges), there are no published human efficacy trials. What exists is:

• Preclinical absorption data in animal models
• Pharmacokinetic studies of oral semaglutide in general (mostly for FDA-approved tablets with SNAC technology)
• Anecdotal patient outcomes shared on telehealth platforms and Reddit
• Clinical trial data for injected semaglutide, which compounders sometimes cite by implication

This doesn't mean compounded oral GLP-1s don't work. It means the evidence that they work as well as advertised is much thinner than the evidence for FDA-approved versions. If you go the compounded route, you're making a bet on pharmacy quality and the plausibility of the absorption mechanism — not on published clinical data.

The oral tirzepatide question

You'll find telehealth companies selling "oral tirzepatide" as drops or lozenges. This is worth understanding clearly: tirzepatide is a 4,813-dalton peptide. It's roughly ten times larger than what's considered orally bioavailable by conventional mechanisms. There is no published human pharmacokinetic data showing meaningful oral absorption of tirzepatide. Eli Lilly itself chose not to pursue oral tirzepatide for exactly this reason — instead developing the small-molecule orforglipron (Foundayo) for the oral market.

In November 2025, a class-action lawsuit (Day v. OpenLoop Health, Case 1:25-cv-01418, D.Del.) was filed alleging misleading marketing of compounded oral tirzepatide. The case is ongoing as of April 2026. We cover this in detail in our dedicated oral tirzepatide guide.

Efficacy — what the trials actually show

The most helpful way to think about GLP-1 efficacy is to compare apples to apples: trial-derived mean weight loss at the maintenance dose over at least one year of treatment. Here's where each drug lands:

Direct head-to-head comparisons don't exist. Every number above comes from a separate trial with different patient populations. But the rank-order has held up across repeated studies: injectable tirzepatide > injectable semaglutide ≈ oral semaglutide 25 mg > orforglipron > Rybelsus.

For compounded oral semaglutide in drop or ODT format: no comparable trial data exists. Providers will sometimes show you marketing studies, user surveys, or outcomes from injectable semaglutide. None of these are equivalent to a phase 3 randomized trial.

Cost comparison across formats

Self-pay monthly pricing, April 2026, starter-dose tier where applicable:

The headline: at starter-dose pricing, FDA-approved and compounded oral GLP-1s are now at rough price parity. That's new. For most of 2024–2025, compounded was the clear price winner by a wide margin. The launch of NovoCare Direct pricing for the Wegovy pill and LillyDirect pricing for Foundayo changed that math dramatically.

Who should consider an oral GLP-1?

Good candidates

• People who genuinely can't or won't use injections (needle phobia, professional constraints, travel frequency)
• People starting GLP-1 therapy who want to begin with the lowest-commitment option
• People already on Rybelsus for diabetes who want to switch to the Wegovy pill for obesity indication
• People who value lower upfront cost over incremental efficacy (roughly 1–2 percentage points of weight loss)

Less obvious candidates

• If you have significant gastroparesis or reflux, injectable may be better tolerated than oral (oral drugs exacerbate upper-GI symptoms for some patients)
• If you have very erratic meal timing, the Wegovy pill's strict fasting window is a real obstacle — consider Foundayo (no food restriction) or injection
• If you have commercial insurance that covers injectable GLP-1s, your monthly cost may actually be lower with an injection
• If you want maximum weight loss and tolerate injections fine, tirzepatide injection still produces the largest effect

Our top provider picks for oral GLP-1

Four editorial picks, each for a different use case. Full reviews are linked for each.